We are live on ! Find out more
XRTX

XORTX Therapeutics
XRTX

6 hedge funds and large institutions have $324K invested in XORTX Therapeutics in 2024 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

689% more capital invested

Capital invested by funds: $41.1K → $324K (+$283K)

8.06% more ownership

Funds ownership: 0.85% → 8.91% (+8.1%)

14% less funds holding

Funds holding: 7 → 6 (-1)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

Holders
6
Holders Change
-1
Holders Change %
-14.29%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$366K
2
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$1.14K

Top Sellers

Rank Fund Capital Flow
1
National Bank of Canada
National Bank of Canada
Quebec, Canada
-$2.52K
2
UBS Group
UBS Group
Switzerland
-$1.86K
3
JP Morgan Chase
JP Morgan Chase
New York
-$1.21K
4
TRCT
Tower Research Capital (TRC)
New York
-$138

XRTX Hedge Fund Activity: Q4 2024 in Review

6 of the 7,608 institutional investors tracked by Wall St. Rank reported a position in XORTX Therapeutics (XRTX) for Q4 2024, worth a combined $324K — up 689% from $41.1K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of XRTX and 1 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 1 added.

The largest buyer was Armistice Capital, opening a new position worth an estimated $366K. The largest seller was National Bank of Canada, cutting an estimated $2.52K.

  • 6 institutional investors held XORTX Therapeutics (XRTX) as of Q4 2024, down from 7 in Q3 2024.
  • Funds reported $324K of XORTX Therapeutics stock for Q4 2024, up 689% quarter-over-quarter.
  • 1 fund opened new XORTX Therapeutics positions in Q4 2024 and 2 closed out, a net change of -1 holder.
  • The largest XORTX Therapeutics buyer in Q4 2024 was Armistice Capital, an estimated $366K added.
  • The largest XORTX Therapeutics seller in Q4 2024 was National Bank of Canada, an estimated $2.52K sold.

Based on aggregated 13F filings for Q4 2024.